Dr Reddy's gets DCGI nod for Zytorvi in esophageal cancer
In short
Dr Reddy's said it got DCGI approval for Zytorvi in India. The drug can be used with cisplatin and paclitaxel for adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma.
This could widen access to first-line treatment for patients in India. The story does not say when the drug will be sold or what it will cost.
What the reporting says
Dr Reddy's Laboratories received DCGI approval for Zytorvi (toripalimab) in India for first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma, according to a company release cited by Business Standard. The approval covers use with cisplatin and paclitaxel and is the drug's second approved indication in the country. The reporting does not state launch timing or pricing.
Why it matters
Dr Reddy's Laboratories received DCGI approval in India for Zytorvi, also known as toripalimab, for use with cisplatin and paclitaxel in first-line treatment of adult patients with unresectable advanced, recurrent or metastatic ESCC. The approval expands the drug's use beyond its earlier indication, making it the second approved use in the country. The reporting does not say when sales will begin, how large the patient pool is, or any commercial terms.